Recent Finacing
Recent Raise
Diasome develops HDV insulin that targets hepatocytes to mimic hepatic insulin exposure, is running multiple Phase 2 T1D trials, and is developing an oral T2D compound.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors